MBody AI Ltd. (MBAI) Stock: Price, Forecast & Analyst Target
Educational signal · not a buy or sell recommendation · How to read this
P/E 0.44 means the share price is 0.44 times one year of earnings per share. Market cap $31.4M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 4, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerMBody AI Ltd. (MBAI) trades at $2.05. Check-Cap Ltd. is a clinical-stage medical diagnostics company specializing in capsule-based screening technology. Their primary focus is on developing a non-invasive alternative for colorectal cancer screening. Market cap: $31.4M, Sector: Technology.
Price as of · Last analyzed: May 4, 2026MBAI stock analysis for 2026: Analysts have set a consensus price target of $10.00 for MBody AI Ltd., suggesting 387.8% upside from the current price of $2.05. Key factors: analyst coverage, company fundamentals.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
MBody AI Ltd. (MBAI) Technology Profile & Competitive Position
Check-Cap Ltd. is a clinical-stage medical diagnostics firm focused on capsule-based screening, primarily for colorectal cancer. Their non-invasive technology aims to disrupt traditional screening methods. With a market cap of $31.4M and a P/E ratio of 0.44, the company operates in the competitive healthcare diagnostics sector.
What Is the Investment Thesis for MBAI?
The company's capsule-based screening technology for colorectal cancer offers a potentially disruptive alternative to traditional methods, addressing patient compliance and convenience. Key value drivers include successful completion of clinical trials, regulatory approvals, and commercialization partnerships. The company's current market capitalization of $31.4M reflects its early stage and associated risks. A P/E ratio of 0.44 may not be indicative of future performance given the company's clinical stage. The primary growth catalyst is achieving FDA approval for its screening technology, which could significantly increase its market value. However, potential risks include clinical trial failures, regulatory hurdles, and competition from established diagnostic methods. Investors should carefully consider the company's financial position and the inherent uncertainties of clinical-stage medical device development.
Based on FMP financials and quantitative analysis
MBAI Key Highlights
Check-Cap Ltd. is a clinical-stage company focused on capsule-based medical diagnostics.
- The company's primary focus is on developing a non-invasive colorectal cancer screening technology.
- The company is based in Isfiya, Israel, with a team of 85 employees.
- David Lontini serves as the CEO, leading the company's strategic direction.
- The company's market capitalization is $31.4M, reflecting its early stage of development.
Who Are MBAI's Competitors?
MBAI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| EXAS Exact Sciences Corporation | $104.91 | 0.00% | $20.0B | — |
| IMXI International Money Express, Inc. | $5.79 | +3.39% | $175M | 68 5-pillar |
| LSAK Lesaka Technologies, Inc. | $3.34 | +2.77% | $289M | 59 5-pillar |
| CINT CI&T Inc. | $2.93 | +0.34% | $373M | 70 5-pillar |
| ALLT Allot Ltd. | $7.97 | +1.01% | $393M | 64 5-pillar |
| PAYS PaySign, Inc. | $10.06 | -0.10% | $572M | 91 5-pillar |
| PICS PICS | $5.11 | +5.80% | $662M | 63 5-pillar |
| CCSI Consensus Cloud Solutions, Inc. | $38.93 | -4.82% | $693M | 81 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MBAI's Key Strengths?
Innovative capsule-based screening technology.
- Non-invasive alternative to traditional methods.
- Potential to improve patient compliance.
- Focus on colorectal cancer screening, a large market.
What Are MBAI's Weaknesses?
Clinical-stage company with no approved products.
- Reliance on successful clinical trial outcomes.
- Dependence on regulatory approvals.
- Limited financial resources.
What Could Drive MBAI Stock Higher?
Completion of ongoing clinical trials for the C-Scan system.
- FDA submission for premarket approval (PMA) of the C-Scan system.
- Announcement of strategic partnerships with healthcare providers.
- Continued research and development efforts to enhance the C-Scan technology.
What Are the Key Risks for MBAI?
Clinical trial failures or delays.
- Regulatory hurdles and delays in obtaining FDA approval.
- Competition from established diagnostic methods.
- Reimbursement challenges from healthcare providers and insurers.
- Limited financial resources and the need for additional funding.
What Are the Growth Opportunities for MBAI?
- FDA Approval and Commercialization: Securing FDA approval for its capsule-based colorectal cancer screening technology represents a significant growth opportunity for Check-Cap. Successful commercialization would allow the company to penetrate the multi-billion dollar colorectal cancer screening market. The timeline for this growth driver is dependent on the completion of clinical trials and the regulatory review process, potentially within the next 2-3 years. A successful launch could establish Check-Cap as a key player in the non-invasive screening market.
- Strategic Partnerships: Forming strategic partnerships with established healthcare providers and distributors can accelerate the adoption of Check-Cap's technology. Collaborations with major hospital networks or diagnostic service providers would provide access to a broader patient base and enhance market penetration. These partnerships could be established within the next 1-2 years, contingent on positive clinical trial results and regulatory progress. Such alliances would significantly boost Check-Cap's commercial reach and market credibility.
- Expansion into New Indications: Leveraging its capsule-based technology platform, Check-Cap can explore applications beyond colorectal cancer screening. Potential expansions include screening for other gastrointestinal disorders or developing diagnostic tools for different medical conditions. This diversification strategy could unlock new revenue streams and reduce reliance on a single product. The timeline for this expansion is estimated at 3-5 years, requiring further research and development efforts. This strategic move would broaden Check-Cap's market potential and long-term growth prospects.
- International Market Entry: Expanding into international markets, particularly Europe and Asia, presents a substantial growth opportunity for Check-Cap. These regions have a growing demand for advanced medical diagnostics and a willingness to adopt innovative technologies. Market entry strategies could involve partnerships with local distributors or establishing a direct presence. The timeline for international expansion is estimated at 2-4 years, contingent on regulatory approvals and market assessments. Successful international expansion would diversify Check-Cap's revenue streams and enhance its global market position.
- Technological Advancements: Continuous innovation and improvement of its capsule-based technology can provide Check-Cap with a competitive edge. Developing more advanced imaging capabilities, enhancing the accuracy of diagnostic results, and improving patient comfort can drive adoption and market share gains. Ongoing research and development efforts are crucial for maintaining technological leadership. These advancements are expected to occur incrementally over the next 1-3 years, driven by internal innovation and external collaborations. Staying at the forefront of technology will solidify Check-Cap's position in the evolving medical diagnostics landscape.
What Are MBAI's Competitive Advantages?
- Proprietary capsule-based screening technology.
- Potential for strong intellectual property protection.
- First-mover advantage in the non-invasive screening market.
- Established relationships with key opinion leaders in gastroenterology.
What Does MBAI Do?
Check-Cap Ltd., established in 2004 and headquartered in Isfiya, Israel, is a clinical-stage medical diagnostics company dedicated to the development of capsule-based screening technology. The company's core focus is on providing innovative solutions for colorectal cancer screening, offering a non-invasive alternative to traditional methods like colonoscopies. Their technology is designed to improve patient compliance and early detection rates, potentially leading to better outcomes. Check-Cap's primary product under development aims to allow individuals to undergo screening in a more convenient and comfortable setting. The company is currently navigating the regulatory approval process to bring its technology to market. Check-Cap operates with a team of 85 employees, led by CEO David Lontini, and is focused on advancing its clinical programs and securing partnerships to expand its reach within the medical diagnostics landscape. The company's strategic location in Israel provides access to a vibrant ecosystem of medical technology innovation and research. As a clinical-stage company, Check-Cap's success hinges on the successful completion of clinical trials and regulatory approvals, which are critical milestones for commercialization.
What Products and Services Does MBAI Offer?
- Develop capsule-based screening technology for medical diagnostics.
- Focus on non-invasive alternatives to traditional screening methods.
- Specialize in colorectal cancer screening.
- Conduct clinical trials to validate their technology.
- Seek regulatory approvals from agencies like the FDA.
- Aim to improve patient compliance with screening guidelines.
- Offer a more convenient and comfortable screening experience.
How Does MBAI Make Money?
- Develop and commercialize capsule-based screening devices.
- Generate revenue through the sale of diagnostic devices.
- Potentially offer diagnostic services through partnerships.
- Seek reimbursement from healthcare providers and insurers.
What Industry Does MBAI Operate In?
Check-Cap Ltd. operates within the medical diagnostics and research industry, a sector characterized by rapid innovation and increasing demand for non-invasive diagnostic solutions. The colorectal cancer screening market is a significant segment, driven by the need for early detection and improved patient outcomes. The competitive landscape includes established players offering traditional screening methods like colonoscopies, as well as emerging companies developing alternative technologies. Check-Cap's capsule-based approach aims to capture a share of this market by addressing patient compliance and convenience. The industry is subject to stringent regulatory requirements and clinical validation, which are critical for market access. The global medical diagnostics market is projected to continue growing, driven by aging populations and increasing healthcare expenditures.
Who Are MBAI's Key Customers?
- Hospitals and clinics that perform diagnostic screenings.
- Gastroenterologists and other medical specialists.
- Patients seeking non-invasive screening options.
- Healthcare providers looking to improve patient compliance.
Research confidence
Broad, current evidence sits behind this analysis.
- ● Scored on 81% of our measures
- ● Price is current
- ● No filing on record
- ● Covered by analysts
Forward Outlook
Wall Street analysts project MBody AI Ltd. revenue of about $4.8M for fiscal 2026, with EPS near $-0.02.
MBAI Valuation & Market Position
With a $31.4M market cap, MBody AI Ltd. sits in the micro-cap segment of the market. Analyst price targets span from $10.00 to $10.00, with a consensus of $10.00. At the current price of $2.05, that implies approximately 388% upside potential.
Key Financial Metrics
Return on equity for MBody AI Ltd. stands at 416.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 55.3%, showing how much profit it generates from its asset base. MBAI trades at a trailing price-to-earnings ratio of 0.44, below the Healthcare sector average of ~21.70x. Its free cash flow yield is -2.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.05 means current liabilities exceed short-term assets, a liquidity point worth watching.
Earnings Track Record
MBody AI Ltd. has beaten Wall Street's EPS estimate in 3 of its last 5 reported quarters — more hits than misses. Reported results have landed about 5.5% below estimates on average.
Company Profile
MBody AI Ltd. operates in the Technology sector. It is headquartered in Mississauga, Canada.
MBAI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Innovative capsule-based screening technology.
- Non-invasive alternative to traditional methods.
- Potential to improve patient compliance.
- Focus on colorectal cancer screening, a large market.
Bear Case
- Clinical-stage company with no approved products.
- Reliance on successful clinical trial outcomes.
- Dependence on regulatory approvals.
- Limited financial resources.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · November 2026
MBAI Latest News
-
MBody AI Doubles Deployment at Mohegan Sun
fiscal.ai · Nov 5, 2026
-
MBody AI Says Mohegan Sun Casino Doubles Size Of Its Product Deployment Under A Three-Year Agreement
benzinga · Nov 5, 2026
-
MBody AI Doubles Deployment at Major Northeast Casino & Entertainment Destination
globenewswire.com · Nov 5, 2026
-
MBody AI Announces Caribe Royale Orlando as New Commercial Partner
fiscal.ai · Oct 23, 2026
MBAI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for MBAI.
Price Targets
Median: $10.00
Consensus vs current price: +387.8%
Stored FMP targets · · Coverage not supplied · an estimate, not advice
MBAI MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for MBAI; grades run from A+ (80-100) to F (below 30).
Latest News
MBody AI Doubles Deployment at Mohegan Sun
MBody AI Says Mohegan Sun Casino Doubles Size Of Its Product Deployment Under A Three-Year Agreement
MBody AI Doubles Deployment at Major Northeast Casino & Entertainment Destination
MBody AI Announces Caribe Royale Orlando as New Commercial Partner
Leadership: David Lontini
CEO
David Lontini serves as the CEO of Check-Cap Ltd., bringing extensive experience in the medical device industry. His background includes leadership roles in various healthcare companies, where he focused on strategic planning, product development, and commercialization. Lontini's expertise spans across multiple therapeutic areas, including diagnostics and medical imaging. He holds advanced degrees in engineering and business administration, providing him with a strong foundation in both technology and management. His career has been marked by a commitment to innovation and improving patient outcomes through advanced medical technologies.
Track Record: Under David Lontini's leadership, Check-Cap Ltd. has focused on advancing its clinical programs and securing key partnerships. He has overseen the company's efforts to navigate the regulatory approval process and prepare for commercialization. Key milestones during his tenure include the completion of clinical trials and the development of strategic collaborations. Lontini's strategic decisions have been instrumental in positioning Check-Cap as a potential leader in the non-invasive colorectal cancer screening market.
MBody AI Ltd. Technology Stock: Key Questions Answered
Is MBAI a good stock to buy?
Stock Expert AI does not rate MBAI buy, sell or hold. MBody AI Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the MBAI stock price today?
The last price recorded on this page for MBody AI Ltd. (MBAI) is $2.05, as of the Nov 19, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the MBAI price target?
The analyst consensus price target for MBody AI Ltd. (MBAI) is $10.00 (range $10.00 to $10.00, median $10.00), per FMP data captured Nov 18, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What is Check-Cap Ltd. Ordinary Share's drug pipeline status?
Check-Cap Ltd. Ordinary Share does not have a traditional drug pipeline. Instead, its primary focus is on the development and commercialization of the C-Scan system, a capsule-based device for colorectal cancer screening.
What are the key factors to evaluate for MBAI?
Evaluate MBAI on fundamentals, analyst consensus, and risk factors. P/E: 0.44x. Analysts target $10.00 (+388%). The company's current market capitalization of $31.4M reflects its early stage and associated risks. Not financial advice.
How frequently does MBAI data refresh on this page?
MBAI's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven MBAI's recent stock price performance?
MBody AI Ltd. (MBAI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative capsule-based screening technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MBAI overvalued or undervalued right now?
MBody AI Ltd. (MBAI) trades at 0.44x earnings. Analysts target $10.00 (+388%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes and regulatory approvals are inherently uncertain.